interferon beta-1a
Selected indexed studies
- Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. (Expert Rev Clin Immunol, 2023) [PMID:37694381]
- Interferon beta 1a. (Baillieres Clin Neurol, 1997) [PMID:10101585]
- Interferon beta-1a for patients with moderate to severe acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. (Pol Arch Intern Med, 2020) [PMID:32250093]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. (2023) pubmed
- Interferon beta 1a. (1997) pubmed
- Interferon beta-1a for patients with moderate to severe acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. (2020) pubmed
- Subcutaneous interferon-beta-1a : new formulation. (2007) pubmed
- Interferon beta-1A for multiple sclerosis. (1998) pubmed
- [Subcutaneous interferon-beta-1a in the treatment of multiple sclerosis]. (2008) pubmed
- Intravenous Interferon β-1a for Severe ARDS. (2020) pubmed
- Intravenous Interferon β-1a for Severe ARDS-Reply. (2020) pubmed
- Interferon beta 1a for secondary progressive multiple sclerosis. (2003) pubmed
- Interferon beta 1a (Rebif®) in relapsing remitting multiple sclerosis. (2021) pubmed